DeepMed Research

INSYS THERAPEUTICS INC

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Study to Determine the Maximum Tolerated Dose of LErafAON in Patients With Advanced Cancer

Phase 1

Completed

Conditions: Neoplasms

First Posted Date: 2005-01-05

Last Posted Date: 2011-07-04

Lead Sponsor: INSYS Therapeutics Inc

Target Recruit Count: 40

Registration Number: NCT00100672

Locations: 🇺🇸
premiere Oncology-Arizona, Scottsdale, Arizona, United States
🇺🇸
Premiere Oncology-Santa Monica, Santa Monica, California, United States

Comparison of Liposome Entrapped Paclitaxel Easy to Use (LEP-ETU) and Taxol® Pharmacokinetics in Patients With Advanced Cancer

Phase 1

Completed

Conditions: Neoplasm

First Posted Date: 2004-12-24

Last Posted Date: 2011-07-04

Lead Sponsor: INSYS Therapeutics Inc

Target Recruit Count: 48

Registration Number: NCT00100139

Locations: 🇺🇸
Cancer Institute of New Jersey - University of Medicine and Dentistry of New Jersey, New Brunswick, New Jersey, United States
🇩🇪
Allgemeines Krankenhaus St. Georg, Hamburg, Germany
🇩🇪
Universitatsklinikum Essen, Essen, Germany

and more 3 locations

IL13-PE38QQR Infusion After Tumor Resection, Followed by Radiation Therapy With or Without Temozolomide in Patients With Newly Diagnosed Malignant Glioma

Phase 1

Completed

Conditions: Glioblastoma Multiforme
Anaplastic Astrocytoma
Oligoastrocytoma

First Posted Date: 2004-08-06

Last Posted Date: 2011-07-04

Lead Sponsor: INSYS Therapeutics Inc

Target Recruit Count: 24

Registration Number: NCT00089427

Locations: 🇺🇸
Duke University Medical Center, Durham, North Carolina, United States
🇺🇸
University of California San Francisco - Dept. of Neurological Surgery, San Francisco, California, United States
🇺🇸
Carolina Neurosurgery & Spine Assoc., Charlotte, North Carolina, United States

and more 3 locations

Liposome Entrapped Paclitaxel Easy to Use (LEP-ETU) in Patients With Advanced Cancer

Phase 1

Completed

Conditions: Neoplasm

First Posted Date: 2004-04-02

Last Posted Date: 2011-07-04

Lead Sponsor: INSYS Therapeutics Inc

Target Recruit Count: 40

Registration Number: NCT00080418

Locations: 🇺🇸
Cancer Institute of New Jersey - University of Medicine and Dentistry of New Jersey, New Brunswick, New Jersey, United States
🇺🇸
Fox Chase Temple Cancer Center - Temple University, Philadelphia, Pennsylvania, United States
🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States

The PRECISE Trial: Study of IL13-PE38QQR Compared to GLIADEL Wafer in Patients With Recurrent Glioblastoma Multiforme

Phase 3

Completed

Conditions: Glioblastoma Multiforme

First Posted Date: 2004-02-10

Last Posted Date: 2011-06-06

Lead Sponsor: INSYS Therapeutics Inc

Target Recruit Count: 300

Registration Number: NCT00076986

Locations: 🇺🇸
City of Hope National Medical Center, Duarte, California, United States
🇺🇸
University of California - Los Angeles Neuro-Oncology Program, Los Angeles, California, United States
🇺🇸
St. Louis University, St. Louis, Missouri, United States

and more 57 locations

Imaging Study of the Distribution of IL13-PE38QQR Infused Before and After Surgery in Adult Patients With Recurrent Malignant Glioma

Phase 1

Completed

Conditions: Malignant Glioma
Glioblastoma Multiforme
Anaplastic Astrocytoma
Anaplastic Oligodendroglioma
Mixed Oligoastrocytoma

First Posted Date: 2003-07-15

Last Posted Date: 2011-06-06

Lead Sponsor: INSYS Therapeutics Inc

Target Recruit Count: 18

Registration Number: NCT00064779

Locations: 🇺🇸
Duke University Medical Center, Durham, North Carolina, United States

Liposome Encapsulated SN38 (LE-SN38) in Patients With Advanced Cancer

Phase 1

Completed

Conditions: Neoplasms

First Posted Date: 2002-10-02

Last Posted Date: 2011-07-04

Lead Sponsor: INSYS Therapeutics Inc

Target Recruit Count: 40

Registration Number: NCT00046540

Locations: 🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
🇺🇸
Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States
🇺🇸
The Ohio State University, Columbus, Ohio, United States

Pre-operative IL13-PE38QQR in Patients With Recurrent or Progressive Malignant Glioma

Phase 1

Completed

Conditions: Malignant Glioma
Glioblastoma Multiforme
Anaplastic Astrocytoma
Mixed Oligoastrocytoma

First Posted Date: 2002-07-12

Last Posted Date: 2011-06-06

Lead Sponsor: INSYS Therapeutics Inc

Target Recruit Count: 80

Registration Number: NCT00041587

Locations: 🇮🇱
Sourasky Medical Center, Tel Aviv, Israel
🇩🇪
University Hospital Kiel, Department of Neurosurgery, Kiel, Germany
🇺🇸
Cleveland Clinic Foundation, Cleveland, Ohio, United States

and more 3 locations

Study to Determine the Maximum Tolerated Dose of LErafAON in Patients With Advanced Solid Tumors

Phase 1

Completed

Conditions: Neoplasms

First Posted Date: 2001-09-25

Last Posted Date: 2011-04-13

Lead Sponsor: INSYS Therapeutics Inc

Target Recruit Count: 30

Registration Number: NCT00024661

Locations: 🇺🇸
University of Chicago Medical Center, Chicago, Illinois, United States
🇺🇸
Temple University Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸
Georgetown University, Washington, District of Columbia, United States

Study of SS1(dsFv)-PE38 (SS1P) Anti-Mesothelin Immunotoxin in Advanced Malignancies: Continuous Infusion for 10 Days

Phase 1

Withdrawn

Conditions: Neoplasms

First Posted Date: 2001-09-25

Last Posted Date: 2014-11-14

Lead Sponsor: INSYS Therapeutics Inc

Registration Number: NCT00024674

Locations: 🇺🇸
NCI/NIH, Bethesda, Maryland, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy